The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04
Open accessAbstract
Purpose: The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients with rectal cancer is unknown. National Surgical Adjuvant Breast and Bowel Project trial R-04 compared four chemotherapy regimens administered concomitantly with RT. Patients and Methods: Patients with clinical stage II or III rectal cancer who were undergoing preoperative RT (45 Gy in 25 fractions over 5 weeks plus a boost of 5.4 Gy to 10.8 Gy in three to six daily fractions) were randomly assigned to one of the following chemotherapy regimens: continuous intravenous infusional fluorouracil (CVI FU; 225 mg/m 2, 5 days per week), with or without intravenous oxaliplatin (50 mg/m 2 once per week for 5 weeks) or oral capecitabine (825 mg/m 2 twice per day, 5 days per week), with or without oxaliplatin (50 mg/m 2 once per week for 5 weeks). Before random assignment, the surgeon indicated whether the patient was eligible for sphincter-sparing surgery based on clinical staging. The surgical end points were complete pathologic response (pCR), sphincter-sparing surgery, and surgical downstaging (conversion to sphincter-sparing surgery). Results: From September 2004 to August 2010, 1,608 patients were randomly assigned. No significant differences in the rates of pCR, sphincter-sparing surgery, or surgical downstaging were identified between the CVI FU and capecitabine regimens or between the two regimens with or without oxaliplatin. Patients treated with oxaliplatin experienced significantly more grade 3 or 4 diarrhea (P < .001). Conclusion: Administering capecitabine with preoperative RT achieved similar rates of pCR, sphincter-sparing surgery, and surgical downstaging compared with CVI FU. Adding oxaliplatin did not improve surgical outcomes but added significant toxicity. The definitive analysis of local tumor control, disease-free survival, and overall survival will be performed when the protocol-specified number of events has occurred.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Self-citationMiwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,136
Self-citationProlongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4911 · Cited by 763
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Frykholm, G. J., Glimelius, B., & Påhlman, L. (1993) · Diseases of the Colon & Rectum · doi:10.1007/bf02049863 · Cited by 538
Wolmark, N. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.388 · Cited by 530
Self-citationGunderson, L. L., Sargent, D. J., Tepper, J. E., Wolmark, N., O'Connell, M. J., Begovic, M., Allmer, C., Colangelo, L., Smalley, S. R., Haller, D. G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.173 · Cited by 436
Self-citationClinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8771 · Cited by 430
Gunderson, L. L., Jessup, J. M., Sargent, D. J., Greene, F. L., & Stewart, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9194 · Cited by 244
Allocation of patients to treatment groups in a controlled clinical study
White, S. J., & Freedman, L. S. (1978) · British Journal of Cancer · doi:10.1038/bjc.1978.124 · Cited by 191
Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule
Cividalli, A., Ceciarelli, F., Livdi, E., Altavista, P., Cruciani, G., Marchetti, P., & Danesi, D. T. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02792-4 · Cited by 101
Das, P., Lin, E. H., Bhatia, S., Skibber, J. M., Rodrı́guez-Bigas, M. A., Feig, B. W., Chang, G. J., Hoff, P. M., Eng, C., Wolff, R. A., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.07.1374 · Cited by 82
Fiducial Intervals: What Are They?
Wang, Y. H. (2000) · The American Statistician · doi:10.1080/00031305.2000.10474520 · Cited by 39
Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6582 · Cited by 32
Ramani, V. S., Myint, A. S., Montazeri, A. H., & Wong, H. (2010) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02323.x · Cited by 22
Yothers, G., Ganz, P. A., Lopa, S., Ko, C. Y., Wickerham, D. L., & Wolmark, N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.391 · Cited by 3
Self-citation
Cited by
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,046
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 944
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0051 · Cited by 827
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
Metadata
- Authors
- O'Connell, M. J., Colangelo, L. H., Beart, R. W., Petrelli, N. J., Allegra, C. J., Sharif, S., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., Parda, D. S., Mohiuddin, M., Arora, A., Evans, L. S., Bahary, N., Soori, G. S., Eakle, J., Robertson, J. M., Moore, D. F., Mullane, M. R., Marchello, B. T., Ward, P. J., Wozniak, T. F., Roh, M. S., Yothers, G., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-06-20
- Volume
- 32
- Issue
- 18
- Pages
- 1927-1934
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100671482
- Cited by
- 439
- References
- 24
- FWCI
- 22.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.